Impact of genomic testing on urologists' treatment preference in favorable risk prostate cancer: A randomized trial.

These findings demonstrate how obtaining prognostic biomarkers that predict negative outcomes before treatment decision-making might influence urologists' preference for recommending aggressive therapy in men eligible for active surveillance.